vs
Ensysce Biosciences, Inc.（ENSC）与Rithm Property Trust Inc.（RPT）财务数据对比。点击上方公司名可切换其他公司
Rithm Property Trust Inc.的季度营收约是Ensysce Biosciences, Inc.的1.8倍（$3.4M vs $1.9M），Rithm Property Trust Inc.净利率更高（95.4% vs -147.0%，领先242.4%），Ensysce Biosciences, Inc.同比增速更快（44.4% vs -39.7%），过去两年Ensysce Biosciences, Inc.的营收复合增速更高（107.9% vs -43.2%）
Ensysce Biosciences是一家临床阶段生物技术公司，专注于开发疼痛管理和肿瘤适应症领域的创新前药疗法，其专有平台可降低阿片类药物滥用风险并提升治疗有效性，面向全球医疗医药市场，重点解决未被满足的临床需求。
Rithm Property Trust Inc.旗下的里思资本是一家总部位于纽约的美国投资管理公司，核心业务聚焦于房地产投资及另类投资领域，是该赛道颇具影响力的专业投资机构。
ENSC vs RPT — 直观对比
营收规模更大
RPT
是对方的1.8倍
$1.9M
营收增速更快
ENSC
高出84.1%
-39.7%
净利率更高
RPT
高出242.4%
-147.0%
两年增速更快
ENSC
近两年复合增速
-43.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.9M | $3.4M |
| 净利润 | $-2.8M | $3.2M |
| 毛利率 | — | — |
| 营业利润率 | -147.8% | 99.6% |
| 净利率 | -147.0% | 95.4% |
| 营收同比 | 44.4% | -39.7% |
| 净利润同比 | 22.3% | 11.2% |
| 每股收益（稀释后） | $-0.51 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENSCRPT
| Q4 25 | $1.9M | $3.4M | ||
| Q3 25 | $493.1K | $4.0M | ||
| Q2 25 | $1.4M | $4.2M | ||
| Q1 25 | $1.3M | $249.0K | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $3.4M | — | ||
| Q4 23 | $515.0K | — | ||
| Q3 23 | $435.4K | $1.1M |
净利润ENSCRPT
| Q4 25 | $-2.8M | $3.2M | ||
| Q3 25 | $-3.7M | $-273.0K | ||
| Q2 25 | $-1.7M | $1.9M | ||
| Q1 25 | $-1.9M | $-3.4M | ||
| Q4 24 | $-3.6M | — | ||
| Q3 24 | $661.8K | — | ||
| Q4 23 | $-3.5M | — | ||
| Q3 23 | $-2.7M | $-5.5M |
营业利润率ENSCRPT
| Q4 25 | -147.8% | 99.6% | ||
| Q3 25 | -758.7% | -6.2% | ||
| Q2 25 | -127.6% | 45.7% | ||
| Q1 25 | -149.1% | -1416.5% | ||
| Q4 24 | -274.3% | — | ||
| Q3 24 | 18.9% | — | ||
| Q4 23 | -612.7% | — | ||
| Q3 23 | -621.8% | -533.4% |
净利率ENSCRPT
| Q4 25 | -147.0% | 95.4% | ||
| Q3 25 | -756.3% | -6.8% | ||
| Q2 25 | -126.4% | 45.1% | ||
| Q1 25 | -147.4% | -1363.1% | ||
| Q4 24 | -273.4% | — | ||
| Q3 24 | 19.4% | — | ||
| Q4 23 | -680.4% | — | ||
| Q3 23 | -618.0% | -526.3% |
每股收益（稀释后）ENSCRPT
| Q4 25 | $-0.51 | $-0.26 | ||
| Q3 25 | $-1.29 | $-0.03 | ||
| Q2 25 | $-0.79 | $0.01 | ||
| Q1 25 | $-1.39 | $-0.08 | ||
| Q4 24 | $-0.89 | — | ||
| Q3 24 | $1.00 | — | ||
| Q4 23 | $-66.47 | — | ||
| Q3 23 | $-0.87 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.3M | $79.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.2M | $291.6M |
| 总资产 | $7.5M | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ENSCRPT
| Q4 25 | $4.3M | $79.3M | ||
| Q3 25 | $1.7M | $81.4M | ||
| Q2 25 | $2.2M | $98.6M | ||
| Q1 25 | $3.1M | $97.4M | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $4.2M | — | ||
| Q4 23 | $1.1M | — | ||
| Q3 23 | $1.5M | $63.9M |
股东权益ENSCRPT
| Q4 25 | $3.2M | $291.6M | ||
| Q3 25 | $1.2M | $291.7M | ||
| Q2 25 | $3.4M | $294.7M | ||
| Q1 25 | $3.0M | $296.1M | ||
| Q4 24 | $3.7M | — | ||
| Q3 24 | $6.9M | — | ||
| Q4 23 | $-322.9K | — | ||
| Q3 23 | $1.5M | $320.2M |
总资产ENSCRPT
| Q4 25 | $7.5M | $1.0B | ||
| Q3 25 | $3.2M | $1.0B | ||
| Q2 25 | $5.6M | $1.0B | ||
| Q1 25 | $4.6M | $1.0B | ||
| Q4 24 | $5.6M | — | ||
| Q3 24 | $9.4M | — | ||
| Q4 23 | $2.7M | — | ||
| Q3 23 | $3.2M | $1.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.5M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -2.56× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ENSCRPT
| Q4 25 | $-1.5M | $-8.3M | ||
| Q3 25 | $-1.9M | $-5.8M | ||
| Q2 25 | $-2.7M | $-25.0K | ||
| Q1 25 | $-1.7M | $-1.6M | ||
| Q4 24 | $-764.1K | — | ||
| Q3 24 | $-1.0M | — | ||
| Q4 23 | $-1.8M | — | ||
| Q3 23 | $-2.3M | $-10.7M |
资本支出强度ENSCRPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 0.0% |
现金转化率ENSCRPT
| Q4 25 | — | -2.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.54× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
